Shengtai makes China facility more efficient

27 October 2008

Shengtai Pharmaceutical, a manufacturer and distributor of pharmaceutical-grade glucose products in China, has completed factory improvements providing technological and environmental best practices in its cornstarch facility.

Shengtai says that the improvement of the water treatment program in the production facility has resulted in a significant reduction of protein deposits from its sewage. These technological enhancements led to the removal of three high-power pumps and a cold water tower, which lowered the plant's monthly electricity usage by approximately 8,000 kWh. Additionally, higher plant efficiency was attained through reduced labor costs and a noticeably streamlined production facility.

"These changes will improve our factory's efficiency and provide cost reductions," said company chief executive Qingtai Liu. "We are dedicated to improving our technology and maintaining a state-of-the-art production facility to ensure the highest-quality products for our customers and the best environment for our workforce," he added.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight